Undisclosed intranasal compound: Phase I started

Serenity began a Phase I trial. The compound was developed using the CPE-215 drug delivery technology from CPEX, which spun out from Bentley Pharmaceuticals Inc. (AMEX:BNT, Exeter, N.H.) earlier this...